Search results for

Following the ECJ's decisions in Kit Kat, Thomson Life and Picaro, Carles Prat asks: is likelihood of confusion taking a break? Further clarification may come in the pending Opel case

Dave A Wyatt of Henry Goh & Co Sdn Bhd in Kuala Lumpur explains how patent applicants in Malaysia should navigate their way through the country’s patent regime to maximize protection of their intellectual property rights

Despite harmonization, there remain significant differences in the way freelancers are treated in the EU member states. Les Christy and Susannah Kendall contrast the situation in common law and civil law jurisdictions and examine how the situation is likely to change in the future

Despite harmonization, there remain significant differences in the way freelancers are treated in the EU member states. Les Christy and Susannah Kendall contrast the situation in common law and civil law jurisdictions and examine how the situation is likely to change in the future

Merger mania has hit the life sciences industry. And it is all because of patents, or rather lack of them. James Nurton examines the role of intellectual property in pharmaceuticals deals

ICANN's new system for settling domain name disputes is already making an impact. In just a couple of months, four victories have been scored by trade mark owners seeking the cyberspace rights to their trade name.

Licensing plant patents

BT is to launch a major licensing push in the US and Canada to exploit value from its 14,000 patents. James Nurton visits the telecoms company’s global research headquarters near Ipswich, England to find out how

Anti-counterfeiting agencies have scored some major victories against copyright pirates in the UK. But enforcement remains an uphill struggle, as Ingrid Hering reports

In one of the most eagerly-awaited patent trials in recent years, Amgen has successfully defended three out of the five patents protecting its best-selling drug Epogen. In a 245-page ruling, Judge William G Young of the US District Court in Boston ruled that Transkaryotic Therapies (TKT) infringed the patents in its experimental drug Dynepo. But he ruled that two further patents on Epogen were not infringed. Dynepo is at present in phase III clinical trials. TKT´ s shares fell over 50% following the decision, while Amgen´ s share price shot up 10%.